Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and 'exit' via the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synergistic SGLT2 and GLP-1R targeting alleviates systemic inflammation-induced and M1 monocyte-driven endothelial dysfunction in coronary artery disease.

Cardiovascular diabetology·2026
Same author

Use of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors in Pulmonary Hypertension.

Circulation. Heart failure·2025
Same author

Publisher Correction: Extensive identification of genes involved in congenital and structural heart disorders and cardiomyopathy.

Nature cardiovascular research·2025
Same author

Reactive oxygen species in tendon injury and repair.

Redox biology·2025
Same author

Contribution of hypoxia-inducible factor 1alpha to pathogenesis of sarcomeric hypertrophic cardiomyopathy.

Scientific reports·2025
Same author

Inflammation and Fibrosis in Progeria: Organ-Specific Responses in an HGPS Mouse Model.

International journal of molecular sciences·2024

Related Experiment Video

Updated: Jun 20, 2026

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

Targeting SGK1 in diabetes.

Florian Lang1, Agnes Görlach, Volker Vallon

  • 1Eberhard-Karls-University of Tuebingen, Department of Physiology, Gmelinstrasse 5, Tuebingen 72076, Germany. florian.lang@uni-tuebingen.de

Expert Opinion on Therapeutic Targets
|September 22, 2009
PubMed
Summary

Serum-and-glucocorticoid-inducible-kinase-1 (SGK1) plays a key role in diabetes development and complications. Targeting SGK1 may offer a therapeutic strategy for managing type 2 diabetes and its associated conditions.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Physiology

Background:

  • Serum-and-glucocorticoid-inducible-kinase-1 (SGK1) is increasingly implicated in the pathophysiology of diabetes.
  • SGK1 exhibits ubiquitous expression and high transcriptional sensitivity to various stimuli like hyperglycemia and ischemia.
  • Its activation by insulin and growth factors involves key signaling pathways including PI3K, PDK1, and mTOR.

Purpose of the Study:

  • To elucidate the pathophysiological role of SGK1 in diabetes development and complications.
  • To explore the molecular mechanisms underlying SGK1 activation and its downstream targets.
  • To investigate the potential of targeting SGK1 as a therapeutic strategy for type 2 diabetes.

Main Methods:

  • Review of existing literature on SGK1 expression, regulation, and function.

Related Experiment Videos

Last Updated: Jun 20, 2026

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

  • Analysis of SGK1's involvement in activating ion channels, carriers, and enzymes.
  • Examination of SGK1's role in regulating transcription factors and its association with diabetes-related phenotypes.

    • Main Results:

    • SGK1 regulates numerous ion channels, carriers, and enzymes crucial for cellular homeostasis.
    • A common SGK1 gene variant is linked to increased blood pressure, obesity, and type 2 diabetes.
    • SGK1 is hypothesized to contribute to fluid retention, hypertension, and fibrosis in diabetic patients.

    Conclusions:

    • SGK1 is a significant factor in the development and progression of diabetes and its complications.
    • Targeting SGK1 presents a promising therapeutic avenue for managing type 2 diabetes.
    • Further research into SGK1 modulation could lead to novel treatments for diabetic nephropathy and other related conditions.